Generate Biomedicines prices $400M IPO at $16/share

Generate Biomedicines, Inc., a clinical-stage generative biology company, priced its initial public offering of 25 million shares of common stock at $16 per share. The Somerville, Massachusetts-based company expects gross proceeds of $400 million before underwriting discounts and commissions and estimated offering expenses payable All shares are being offered Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities and Cantor are acting as book-running managers. A registration statement relating to these securities was declared effective